Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. executive Joseph Manhede, the Principal Accounting Officer, filed an initial ownership report showing his equity position in the company. The filing reflects 52,576 shares of Common Stock held directly, represented by restricted stock units that convert to common shares on a one-for-one basis.
These RSUs were granted on May 4, 2026. One-third of the units will vest on May 4, 2027, with the remaining units vesting in equal quarterly installments over the following two years. The filing does not report any open-market purchases or sales, only the existing equity award and its vesting schedule.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Manhede Joseph
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 52,576 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Common Stock equivalent: 52,576 shares
Initial vesting portion: One-third of RSUs
Remaining vesting period: Two years
+1 more
4 metrics
Common Stock equivalent
52,576 shares
Beneficial ownership following RSU grant
Initial vesting portion
One-third of RSUs
Vests on May 4, 2027
Remaining vesting period
Two years
Remaining RSUs vest in equal quarterly installments
Open-market transactions
0
No buy or sell transactions reported in Form 3
Key Terms
restricted stock units ("RSUs"), Common Stock, Principal Accounting Officer
3 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Common Stock financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Principal Accounting Officer financial
"officer_title": "Principal Accounting Officer""
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
FAQ
What did Rocket Pharmaceuticals (RCKT) executive Joseph Manhede report on this Form 3?
Joseph Manhede reported his initial ownership of Rocket Pharmaceuticals equity. The filing shows he directly holds restricted stock units that convert into 52,576 shares of Common Stock, documenting his starting position as Principal Accounting Officer without reporting any open-market transactions.
What are the terms of Joseph Manhede’s RSU grant at Rocket Pharmaceuticals (RCKT)?
The RSUs were granted on May 4, 2026 and convert one-for-one into Common Stock. One-third of the RSUs will vest on May 4, 2027, with the remaining units vesting in equal quarterly installments over the subsequent two years.
Does this Rocket Pharmaceuticals (RCKT) Form 3 show any stock purchases or sales?
The Form 3 does not report any stock purchases or sales by Joseph Manhede. It only discloses his initial ownership position through restricted stock units and their vesting schedule, rather than recording open-market buying or selling activity.
What role does Joseph Manhede hold at Rocket Pharmaceuticals (RCKT)?
Joseph Manhede is identified as the Principal Accounting Officer of Rocket Pharmaceuticals. His Form 3 filing establishes his initial beneficial ownership of restricted stock units that convert into 52,576 shares of Common Stock, aligning his compensation with shareholder interests.